SCHEMBL4714918

SCHEMBL4714918

COC(=O)CC1CCN(C(=O)OC(C)(C)C)Cc2cc(NC(=O)OCc3ccc([N+](=O)[O-])cc3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 2/20 0.38
MAPK1 P28482 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DRD2 P14416 1/20 0.37
NAMPT P43490 1/20 0.37
MMP1 P03956 2/20 0.37
MMP2 P08253 2/20 0.37
MMP9 P14780 2/20 0.37
MMP8 P22894 2/20 0.37
MMP13 P45452 2/20 0.37
F10 P00742 1/20 0.36
YAP1 P46937 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
PTPN2 P17706 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714474 0.77 GPR119 (0.47) ALDH1A1NPC1RAB9ANAMPTGPR119
SCHEMBL4715294 0.76 CXCR4 (0.40)
SCHEMBL4721313 0.76 STS (0.46) ALDH1A1NAMPT
SCHEMBL4718766 0.76 USP30 (0.42) ALDH1A1NPC1RAB9AMAPK1NAMPT
SCHEMBL4714943 0.76 NR1H2 (0.56) ALDH1A1NPC1RAB9AMAPTHTT
SCHEMBL4718638 0.74 TGFBR1 (0.44) ALDH1A1NPC1RAB9AMAPK1NAMPT
SCHEMBL4716513 0.74 TGFBR1 (0.54)
SCHEMBL4789524 0.73 RAB9A (0.59) ALDH1A1NPC1RAB9ALMNAMAPT
SCHEMBL7463372 0.71 ALDH1A1 (0.47) ALDH1A1LMNAMAPTNAMPTGPR119
SCHEMBL8449180 0.71 ALDH1A1 (0.47) ALDH1A1LMNAMAPTNAMPTGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed